Key Highlights
- Worldwide Revenue rose 15.0% to USD 154.5 million, with United States revenue up 17.1% to USD 128.0 million.
- Gross Margin reached 77.3%, up 180 basis points, and Net Income was USD 4.1 million, or USD 0.08 per share.
- Adjusted EBITDA rose 51% to USD 26.8 million, and adjusted EPS was USD 0.18 versus a USD 0.01 loss.
- Full-year revenue is now projected at USD 606 to 610 million, with adjusted EBITDA of USD 91 to 94 million.
Revenue and Profitability
AtriCure, Inc. (NASDAQ:ATRC), a maker of surgical treatments for atrial fibrillation, left atrial appendage management and post-operative pain management, reported third-quarter 2026 worldwide revenue of USD 154.5 million, an increase of 15.0% from the prior year, or 15.1% on a constant currency basis. United States revenue was USD 128.0 million, up USD 18.7 million or 17.1%. International revenue was USD 26.4 million, up USD 1.4 million or 5.8%, with growth in all franchises.
Gross profit was USD 119.4 million compared with USD 101.3 million, and gross margin of 77.3% was 180 basis points higher on favorable product and geographic mix. Income from operations was USD 4.4 million versus USD 0.2 million, and net income was USD 4.1 million, or USD 0.08 per share. Adjusted EBITDA was USD 26.8 million, up USD 9.0 million.
Analyst estimates were EPS of negative USD 0.06 against reported EPS of USD 0.08, and revenue of USD 151.1 million against reported revenue of USD 154.4 million.
Franchise Detail
President and Chief Executive Officer Michael Carrel said adoption of new technologies is driving growth and expanding profitability, and that rapid progress on the BoxX-NoAF clinical trial reinforces confidence in the opportunities ahead. In the United States, pain management revenue rose to USD 28.1 million from USD 20.8 million on sales of the cryoSPHERE MAX probe, and appendage management revenue rose to USD 51.6 million from USD 45.5 million on the AtriClip FLEX-Mini and PRO-Mini devices. Open ablation revenue rose to USD 43.0 million from USD 35.6 million, helped by the EnCompass clamp.
Minimally invasive ablation fell to USD 5.4 million from USD 7.4 million as physicians reduced hybrid procedures and adopted pulsed field ablation catheters.
Balance Sheet and Guidance
Cash and cash equivalents were USD 187.0 million at September 30, 2026, compared with USD 167.4 million at the end of 2025. Inventories rose to USD 87.3 million from USD 78.5 million and Accounts Receivable rose to USD 76.1 million from USD 66.7 million, while property and equipment grew to USD 66.7 million from USD 39.1 million.
Management now projects full-year 2026 revenue of USD 606 million to USD 610 million and adjusted EBITDA of USD 91 million to USD 94 million. Net income per share is projected at USD 0.21 to USD 0.27 and adjusted Earnings Per Share at USD 0.40 to USD 0.46. Management also projects continued positive cash generation for 2026.
Items to Follow
Adoption of pulsed field ablation in hybrid procedures, pain management growth and enrollment progress in BoxX-NoAF are the items to follow. Gross margin gains have so far outpaced operating costs, since income from operations reached USD 4.4 million on revenue growth of 15%.






Please wait processing your request...